CDK4 and osteosarcoma: Our results illustrate that loss of CDKN2A and/or CDKN2B are early events in the development of osteosarcoma, and that these events can be targeted by CDK4/CDK6 inhibition, which might be used as a novel therapeutic option in approximately 20–23% of the patients.